GlassScriptPhysician profile
Michael W Peters
NPI 1477501906
$17,315.21
in general payments reported to CMS, 2019-2025
57 companies · $2,604 in 2025
The $2,604 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,442 · 2020: $2,156 · 2021: $2,480 · 2022: $2,388 · 2023: $2,410 · 2024: $2,835 · 2025: $2,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,611 · Education: $125 · Consulting Fee: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,611.18 |
| Education | $124.56 |
| Consulting Fee | $112.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,152.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,075.24 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,226.24 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,085.28 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $1,042.26 | 2019-2025 | Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $917.44 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $805.89 | 2019-2025 | Synjardy, Tradjenta, Jardiance |
| Pfizer INC. | $790.49 | 2019-2025 | |
| Amarin Pharma, INC. | $764.99 | 2019-2022 | |
| Glaxosmithkline, LLC. | $553.30 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $510.62 | 2019-2025 | Verquvo, Capvaxive, Belsomra |
| Allergan, INC. | $448.03 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $392.78 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $385.99 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $365.06 | 2019-2025 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $360.62 | 2023-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $326.00 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $299.75 | 2019-2022 | |
| Dexcom, INC. | $249.80 | 2021-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $242.32 | 2024-2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $209.15 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $208.48 | 2024-2025 | Voquezna |
| Smith+Nephew, INC. | $195.28 | 2022-2025 | Grafix, Renasys Go V2 Home |
| Esperion Therapeutics, INC. | $166.90 | 2020-2025 | Nexletol |
| Biogen, INC. | $160.44 | 2021 | |
| Astellas Pharma US INC | $138.84 | 2020-2024 | Veozah |
| Eisai INC. | $137.20 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $124.63 | 2021-2023 | Nuzyra |
| Adma Biomanufacturing LLC | $112.83 | 2023 | |
| Sunovion Pharmaceuticals INC. | $79.10 | 2022 | |
| Exact Sciences Corporation | $72.88 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Arbor Pharmaceuticals, INC. | $52.84 | 2020-2021 | |
| Antares Pharma, INC. | $51.41 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Daiichi Sankyo INC. | $49.91 | 2019-2022 | |
| Axsome Therapeutics, INC. | $46.58 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $41.08 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $34.51 | 2023-2025 | Ztlido |
| Aytu Biopharma, INC. | $34.39 | 2020 | |
| Idorsia Pharmaceuticals US INC | $33.89 | 2023 | Quviviq |
| Kci USA, INC. | $30.62 | 2022 | |
| Philips North America LLC | $29.01 | 2024-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Ck7) Extended Holter |
| Seqirus USA INC | $26.01 | 2025 | Fluad |
| E.R. Squibb & Sons, L.L.C. | $24.53 | 2019-2021 | |
| Bioventus LLC | $22.44 | 2022 | |
| Solventum Corporation | $21.63 | 2025 | Kerramax Care, 3m Cavilon, Promogran Prisma |
| Inspire Medical Systems, INC. | $20.75 | 2024 | Inspire |
| Abbott Laboratories | $20.61 | 2024 | Freestyle Libre 3 |
| Csl Behring | $20.36 | 2020 | |
| Mylan Specialty L.P. | $19.73 | 2024 | Yupelri |
| Integra Lifesciences Corporation | $19.47 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Medicure Pharma INC. | $18.20 | 2021 | |
| Urgo Medical North America, LLC | $17.80 | 2024 | Urgoclean Ag |
| Ardelyx, INC. | $17.59 | 2024 | Ibsrela |
| Sanofi Pasteur INC. | $17.38 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $16.65 | 2023 | Inpefa |
| Avanir Pharmaceuticals, INC. | $15.30 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.